Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis

Figure 1 Patients: Analysis sets and drop outs.

Figure 2 Patients (ITT analysis) in clinical remission or improved during a 4-mo follow-up period without additional apheresis therapy.

Figure 3 Course of clinical and endoscopic activity indices (CAI, EI) throughout the apheresis treatment. ^aP<0.05 vs Et at wk 6, ^bP<0.01 vs Et at wk 5, ^dP<0.01 vs Et at wk 4, ^fP<0.05 vs Et at wk 3.

Figure 4 Course of neutrophil, lymphocyte, and monocyte counts as well as CRP between the beginning and wk 6 of the study (numbers are given as means; no significant differences).